AACR 2025: A Spotlight on New Drugs
AACR 2025 saw 7,000 abstracts, with close to 400 new Oncology drugs disclosed.
This infographic provides insights into the novel targets, emerging therapeutic classes and companies making advances within the Oncology drug development landscape.
Key Highlights Include:
- Therapeutic Classes: Biologics dominated, with bispecific and dual-payload ADCs taking center stage
- Top Targets: CDH17 emerged as the leading novel target, especially in gastrointestinal (GI) malignancies
- Developers: Chinese Biopharma developers are making notable strides, particularly in biological therapies
You May Also Be Interested In…
Learn More About Oncology
- The Most Comprehensive Way to Search the Oncology Drug Development Landscape: Unique search ontologies based on Oncology drug and trial characteristics
- Market Leading Approach to Oncology Preclinical & Clinical Data Curation: Manual curation of key Oncology research and development data points by Oncology research scientists
- Seamlessly Integrate Commercial & Scientific Data all in One Place: Search Oncology company and deal data based on their pipeline and technologies.
- Unrivalled Granularity in Reports & Analysis: Our search ontology and technology indexing enable comprehensive analysis not seen elsewhere.
What is Beacon?
Beacon is the essential intelligence platform for R&D decision-makers working in pharma and biotech, offering unique technology and drug datasets for complex therapeutics and disease areas.
Our market-defining proprietary ontologies, manual data curation, and accurate and comprehensive life science data, provide our customers with unparalleled visibility of the drug, trial and commercial landscape.
This is why 24 of the top 25 pharmaceutical companies trust Beacon to power their critical pipeline, competitive, and commercial decisions.
We’d welcome the opportunity to show you how Beacon can transform your data strategy. Book your personalized demonstration today!
